Thrombosis
News
FDA grants drug orphan designation for PNH
The US Food and Drug Administration (FDA) has granted orphan drug designation to RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria...
From the Journals
Stopping statins after stroke may up recurrent stroke risk
Nearly 20% of patients 3-6 months after a stroke, in a Taiwanese database, were not using statins. Read the findings of a large retrospective...
News
Product granted fast track designation for aTTP
The US Food and Drug Administration (FDA) has granted fast track designation to caplacizumab, an anti-von Willebrand factor (vWF) nanobody being...
News
FDA approves generic tranexamic acid
Zydus Cadila has received approval from the US Food and Drug Administration (FDA) to market a tranexamic acid product for use in patients with...
Conference Coverage
Product can reduce, prevent bleeding in kids with FXD
BERLIN—Results of a phase 3 study suggest prophylaxis with plasma-derived factor X (pdFX, Coagadex®) prevents or reduces bleeding episodes in...
Conference Coverage
Death is most frequent major adverse outcome after VTE
BERLIN—Data from the GARFIELD-VTE registry showed that, in the first 6 months after a patient was diagnosed with venous thromboembolism (VTE),...
Conference Coverage
RNAi therapeutic reduces ABR in hemophilia A and B
BERLIN—Researchers have reported positive results from an ongoing phase 2 trial of fitusiran in patients with hemophilia A or B, with or without...
Conference Coverage
Gene therapy maintains normal FVIII levels long-term
BERLIN—New research suggests the investigational gene therapy BMN 270 can allow patients with severe hemophilia A to maintain normal factor VIII (...
Conference Coverage
Watchman device for AF patients ineligible for oral anticoagulation gains support from 1-year registry outcomes
PARIS – EWOLUTION study provides reassurance for the patient group left behind in prior trials and FDA approval of the device.
Conference Coverage
Idarucizumab reverses effects of dabigatran in emergencies
BERLIN—Final results from the RE-VERSE AD trial suggest idarucizumab can reverse the anticoagulant effect of dabigatran etexilate mesylate in...
Conference Coverage
Idarucizumab reversed dabigatran completely and rapidly in study
One drug reversed the anticoagulant effect of another completely and rapidly.